Fig. 2

The antibody titers against AS, Omicron BA.2 and BA.5 in the third homologous inactivated vaccine boosted healthy individuals, ∆871 BA.2 and BA.2 breakthrough infected patients. A–C Binding antibody IgG titers against AS RBD (A), Omicron BA.2 RBD (B) and BA.5 RBD (C) in third homologous inactivated vaccine boosted healthy individuals, ∆871 BA.2 and BA.2 breakthrough infected patients with completion of two doses inactivated vaccine scheme or homologous booster. D–F Binding antibody IgG titers against AS RBD (D), Omicron BA.2 RBD (E) and BA.5 RBD (F) in ∆871 BA.2 and BA.2 breakthrough infected adolescents and adults. G–I neutralizing antibodies (NAbs) titers against AS (G), Omicron BA.2 (H) and BA.5 (I) in ∆871 BA.2 and BA.2 breakthrough infected patients with completion of two doses inactivated vaccine scheme or homologous booster. J–L NAbs titers against AS (J), Omicron BA.2 (K) and BA.5 (L) in ∆871 BA.2 and BA.2 breakthrough infected adolescents and adults. Data presented were from 3-independent experiments and analyzed using the two-sided Mann–Whitney U-test. Error bars represent geometric mean titers (GMTs) and 95% confidence interval (CI)